AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) – Equities researchers at Jefferies Group upped their FY2017 earnings estimates for AcelRx Pharmaceuticals in a research report issued on Tuesday. Jefferies Group analyst M. Andrews now expects that the specialty pharmaceutical company will post earnings per share of ($1.00) for the year, up from their prior estimate of ($1.02). Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for AcelRx Pharmaceuticals’ Q4 2017 earnings at ($0.21) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($0.85) EPS, FY2020 earnings at ($1.14) EPS and FY2021 earnings at ($0.93) EPS.
Several other research analysts have also weighed in on ACRX. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Roth Capital reiterated a “buy” rating and set a $12.50 price objective on shares of AcelRx Pharmaceuticals in a report on Thursday, August 10th. Finally, Royal Bank Of Canada cut their price objective on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, October 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.83.
AcelRx Pharmaceuticals (ACRX) opened at $2.07 on Thursday. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Perennial Advisors LLC acquired a new stake in AcelRx Pharmaceuticals during the 3rd quarter worth approximately $138,000. Geller Family Office Services LLC acquired a new stake in AcelRx Pharmaceuticals during the 3rd quarter worth approximately $460,000. Bank of New York Mellon Corp increased its position in AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after purchasing an additional 6,942 shares in the last quarter. Virtu KCG Holdings LLC increased its position in AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 101,742 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in AcelRx Pharmaceuticals during the 2nd quarter worth approximately $319,000. 23.09% of the stock is owned by hedge funds and other institutional investors.
In other AcelRx Pharmaceuticals news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $1.90 per share, with a total value of $57,000.00. Following the transaction, the director now owns 150,000 shares in the company, valued at $285,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total transaction of $53,751.69. Following the sale, the insider now directly owns 16,379 shares of the company’s stock, valued at approximately $86,644.91. The disclosure for this sale can be found here. In the last three months, insiders have purchased 72,000 shares of company stock valued at $178,980. Corporate insiders own 28.10% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.